Fibromyalgia is a high-impact and prevalent condition. Its clinical features include widespread pain and tenderness - often associated with high levels of poor-quality sleep - fatigue and cognitive dysfunction. The mechanism leading to fibromyalgia development is associated with a change in the sensitivity of the pain-related nervous system, as well as other sensory systems. In turn, emotional distress plays a facilitatory role in this process. Non-pharmacological management focuses on education, exercise, and psychological strategies. This article describes the evidence-based therapies that have been evaluated for the pharmacological management of fibromyalgia. Information on the drugs that modulate the sensitisation process, including serotonin-noradrenaline reuptake inhibitors and gabapentinoids, and several drugs with other relevant targets, is detailed; and the lack of benefit of pure opioids is also highlighted.